1. Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D (2013) CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung cancer (Amsterdam, Netherlands) 80: 242-248 doi:10.1016/j.lungcan.2013.02.004
2. Remon J, Le Rhun E, Besse B (2017) Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer treatment reviews 53: 128-137 doi:10.1016/j.ctrv.2016.12.006
3. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT (2013) The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8: 1570-1573 doi:10.1097/JTO.0000000000000029
4. Cheng H, Perez-Soler R (2018) Leptomeningeal metastases in non-small-cell lung cancer. The Lancet Oncology 19: e43-e55 doi:10.1016/s1470-2045(17)30689-7
5. Yin K, Li Y-S, Zheng M-M, Jiang B-Y, Li W-F, Yang J-J, Tu H-Y, Zhou Q, Zhong W-Z, Yang X-N, Chen H-J, Yan H-H, Li L-L, Wu Y-L, Zhang X-C (2019) A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. Lung cancer (Amsterdam, Netherlands) 131: 134-138 doi:10.1016/j.lungcan.2019.03.015
6. Le Rhun E, Galanis E (2016) Leptomeningeal metastases of solid cancer. Current opinion in neurology 29: 797-805 doi:10.1097/wco.0000000000000393
7. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England journal of medicine 371: 2167-2177 doi:10.1056/NEJMoa1408440
8. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L (2015) Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33: 1881-1888 doi:10.1200/jco.2014.59.0539
9. Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ (2015) Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. Journal of medical economics 18: 312-322 doi:10.3111/13696998.2014.1003644
10. Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Perol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nuesch E, Balas B, Camidge DR (2018) Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Annals of oncology : official journal of the European Society for Medical Oncology 29: 2214-2222 doi:10.1093/annonc/mdy405
11. Ou SH, Sommers KR, Azada MC, Garon EB (2015) Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. The oncologist 20: 224-226 doi:10.1634/theoncologist.2014-0309
12. Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF (2015) Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung cancer (Amsterdam, Netherlands) 89: 255-261 doi:10.1016/j.lungcan.2015.05.023
13. Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ (2016) Leptomeningeal metastasis: Clinical experience of 519 cases. European journal of cancer (Oxford, England : 1990) 56: 107-114 doi:10.1016/j.ejca.2015.12.021
14. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Ruda R, Preusser M, Board EE, Board EE, Comm EG (2017) EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Annals of Oncology 28: 84-99 doi:10.1093/annonc/mdx221
15. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS (2016) Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34: 2858-2865 doi:10.1200/jco.2015.63.5888
16. Remon J, Rhun EL, Besse B (2016) Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era Cancer treatment reviews
17. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet (London, England) 390: 29-39 doi:10.1016/s0140-6736(17)30565-2
18. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T (2017) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine 377: 829-838 doi:10.1056/NEJMoa1704795
19. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. The Lancet Oncology 17: 234-242 doi:10.1016/s1470-2045(15)00488-x
20. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT (2015) Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10: 232-236 doi:10.1097/jto.0000000000000455
21. Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT (2016) Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34: 2866-2873 doi:10.1200/jco.2015.65.5936
22. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E (2017) Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology 18: 874-886 doi:10.1016/s1470-2045(17)30339-x
23. LQ C, F B, EM B, F B, M S (2019) Results of the ASCEND-7 phase II study evaluating ALK inhibitor ceritinib in patients with ALK+ non-small cell lung cancer metastatic to the brain. ESMO Congress Abstract 1478O doi:https://
www.annalsofoncology.org/article/S0923-7534(19)59686-7/fulltext
24. Gaye E, Geier M, Bore P, Guilloïque M, Lucia F, Quéré G, Gouva S, Robinet G, Descourt R (2019) Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung cancer (Amsterdam, Netherlands) 133: 1-3 doi:10.1016/j.lungcan.2019.04.013
25. R C, MJ H, C G, A D, DR C (2019) Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of oncology 30 Suppl 2: ii48 doi:10.1093/annonc/mdz063.004
26. Pellerino A, Internò V, Muscolino E, Mo F, Bruno F, Pronello E, Franchino F, Soffietti R, Rudà R (2020) Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances. Journal of Cancer Metastasis and Treatment 2020 doi:10.20517/2394-4722.2020.80
27. Wu YL, Zhou L, Lu Y (2016) Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis. Oncology letters 12: 1301-1314 doi:10.3892/ol.2016.4783
28. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 7: 382-385 doi:10.1097/JTO.0b013e3182398e4f
29. Liao B-C, Lee J-H, Lin C-C, Chen Y-F, Chang C-H, Ho C-C, Shih J-Y, Yu C-J, Yang JC-H (2015) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology 10: 1754-1761 doi:10.1097/jto.0000000000000669
30. Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, Lin T, Wu J, Wang W, Xu S, Liu D, Lu M, Zhu D, Chen L, Cai L, Zhou C (2020) Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiation oncology (London, England) 15: 185 doi:10.1186/s13014-020-01627-y
31. (2020) Central Nervous System Cancers: leptomeningeal Metastases (2020). v.2.2020 doi:Available from: http://www.nccn.org